Secondary stroke prevention in atrial fibrillation: A challenge in the clinical practice

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Tanislav, Christian ^a   Milde, Sonja ^b   Schwartzkopff, Sabine ^c   Sieweke, Nicole ^a   Krämer, Heidrun H ^a   Juenemann, Martin ^a   Misselwitz, Björn ^d   Kaps, Manfred ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b DRESDEN INTERNATIONAL UNIVERSITY   (Germany)

^c AOK Division of the Federal State of Hesse   (Germany)

^d Geschaftsstelle Qualitatssicherung Hessen   (Germany)

Author keywords

Atrial fibrillation; New oral anticoagulants; Secondary prevention; Stroke

Indexed keywords

ANTICOAGULANT AGENT;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISABILITY; FEMALE; FOLLOW UP; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL DISEASE; PRESCRIPTION; REGISTER; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; COMPLICATION; FACTUAL DATABASE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 84908066621     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0195-y     Document Type: Article

References (18)

1. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342:1255-1262..
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. 10.1056/NEJMoa0905561, 19717844.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. 10.1056/NEJMoa1107039, 21870978.
4. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012, 11:315-322. 10.1016/S1474-4422(12)70042-X, 22402056.
5. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002, 288:2441-2448. 10.1001/jama.288.19.2441, 12435257.
6. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011, 342:d124. 10.1136/bmj.d124, 21282258.
7. Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2009, 137:263-272. 10.1378/chest.09-1584, 19762550.
8. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007, 370:493-503. 10.1016/S0140-6736(07)61233-1, 17693178.
9. Russolillo A, Di Minno MN, Tufano A, Prisco D, Di MG. Filling the gap between science & clinical practice: prevention of stroke recurrence. Thromb Res 2012, 129:3-8. 10.1016/j.thromres.2011.08.012, 21907395.
10. Dinh T, Nieuwlaat R, Tieleman RG, Buller HR, van Charante NA, Prins MH, Crijns HJ. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands-The EXAMINE-AF study. A questionnaire survey. Int J Clin Pract 2007, 61:24-31. 10.1111/j.1742-1241.2006.01241.x, 17229177.
11. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Lopez-Sendon J, Vardas PE, Aliot E, Santini M, Crijns HJ. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006, 27:3018-3026. 10.1093/eurheartj/ehl015, 16731536.
12. Foerch C, Misselwitz B, Sitzer M, Berger K, Steinmetz H, Neumann-Haefelin T. Difference in recognition of right and left hemispheric stroke. Lancet 2005, 366:392-393. 10.1016/S0140-6736(05)67024-9, 16054939.
13. Stolz E, Hamann GF, Kaps M, Misselwitz B. Regional differences in acute stroke admission and thrombolysis rates in the German federal state of Hesse. Dtsch Arztebl Int 2011, 108:607-611. 21966319.
14. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di PG, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010, 9:1157-1163. 10.1016/S1474-4422(10)70274-X, 21059484.
15. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745-752. 10.7326/0003-4819-141-10-200411160-00005, 15545674.
16. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115:2689-2696. 10.1161/CIRCULATIONAHA.106.653048, 17515465.
17. Pisters R, Nieuwlaat R, de Vos CB, Crijns HJ. Comprehensive upstream treatment for atrial fibrillation, when and how?. Europace 2009, 11:397-399. 10.1093/europace/eup050, 19307280.
18. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372. 10.1161/CIRCULATIONAHA.110.004747, 21576658.